Integration/Diversification: NeutralVertically integrated: No. It will produce only, and rely on industry channels to distribute the drug
Horizontally diversified: GW has several drugs in the pipeline, so they are trying to be diversified

Financials: Neutral(no revenue yet from new Epidiolex drug, and costs are still very high.)
Earnings/Revenue/Cost control: $460 mil

Previous ProjectGT Biopharma

Next ProjectHiku Brands

Risk of Prosecution for Marijuana-Related Companies. If you are considering investing in a company that is connected to the marijuana industry, be aware that marijuana-related companies may be at risk of federal, and perhaps state, criminal prosecution. The Department of Treasury recently issued guidance noting: “[T]he Controlled Substances Act (“CSA”) makes it illegal under federal law to manufacture, distribute, or dispense marijuana. Many states impose and enforce similar prohibitions. Notwithstanding the federal ban, as of the date of this guidance, 20 states and the District of Columbia have legalized certain marijuana-related activity.”